CSL Names Gordon Naylor Interim CEO with USD 4 Million Equity Grant

Leadership Transition at CSL

CSL Limited, a global leader in plasma therapies and vaccines, has announced a significant leadership change with the retirement of Dr Paul McKenzie as CEO and Managing Director, effective 10 February 2026. McKenzie’s departure closes a chapter marked by steady navigation through the pandemic and notable product innovations.

Stepping into the role on an interim basis is Gordon Naylor, a seasoned CSL veteran with 33 years of service. Naylor’s appointment, effective 11 February, is indefinite until a permanent CEO is appointed. His deep institutional knowledge and prior leadership roles, including Chief Financial Officer and President of Seqirus, position him well to maintain momentum during this transitional period.

McKenzie’s Legacy and Achievements

During his three years as CEO, McKenzie steered CSL through the turbulent COVID-19 era, stabilising manufacturing and supply chains while expanding plasma collection volumes beyond pre-pandemic levels. His tenure saw the launch of pioneering therapies such as HEMGENIX, the world’s first gene therapy for haemophilia B, and ANDEMBRY for hereditary angioedema.

McKenzie also championed operational transformation initiatives, including the Horizon 1 and Horizon 2 programs aimed at improving plasma yield and efficiency. His leadership laid a robust foundation for CSL’s future growth, underscored by investments in research and development and the establishment of a new vaccine facility in Melbourne.

Interim CEO Gordon Naylor’s Mandate

Gordon Naylor’s appointment reflects the board’s confidence in his ability to guide CSL through this interim phase. Having played a pivotal role in CSL’s rise to global prominence, including key acquisitions and infrastructure projects like the Broadmeadows plasma facility, Naylor brings a wealth of operational and strategic expertise.

His immediate focus will be on executing CSL’s ongoing strategic transformation and delivering value to patients, public health, and shareholders. Notably, Naylor’s remuneration package includes a fixed annual salary of approximately USD 2 million and a one-off equity grant valued at around USD 4 million, reflecting the importance of his stewardship during this period.

Looking Ahead

The board has initiated a search for a permanent CEO, with Naylor’s interim leadership providing stability and continuity. Investors and industry watchers will be keen to see how this transition influences CSL’s strategic direction, particularly in innovation and global market expansion.